A Closer Look at Bristol-Myers Squibb's Options Market Dynamics

Whales with a lot of money to spend have taken a noticeably bearish stance on Bristol-Myers Squibb.

Looking at options history for Bristol-Myers Squibb BMY we detected 19 trades.

If we consider the specifics of each trade, it is accurate to state that 15% of the investors opened trades with bullish expectations and 84% with bearish.

From the overall spotted trades, 17 are puts, for a total amount of $1,018,605 and 2, calls, for a total amount of $71,978.

Projected Price Targets

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $41.0 to $72.5 for Bristol-Myers Squibb during the past quarter.

Volume & Open Interest Development

Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Bristol-Myers Squibb's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Bristol-Myers Squibb's significant trades, within a strike price range of $41.0 to $72.5, over the past month.

Bristol-Myers Squibb 30-Day Option Volume & Interest Snapshot

Biggest Options Spotted:

About Bristol-Myers Squibb

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.

After a thorough review of the options trading surrounding Bristol-Myers Squibb, we move to examine the company in more detail. This includes an assessment of its current market status and performance.

Bristol-Myers Squibb's Current Market Status

• With a volume of 8,465,365, the price of BMY is down -1.19% at $50.86.
• RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.
• Next earnings are expected to be released in 48 days.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you want to stay updated on the latest options trades for Bristol-Myers Squibb, Benzinga Pro gives you real-time options trades alerts.